Regulatory NewsBREAK: CMS Issues Final Negotiated Prices for Initial Price Applicability Year 2026
On Aug. 15, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Final Negotiated Prices for Initial Price Applicability Year 2026 under the Inflation Reduction Act (IRA). The drugs selected for this negotiation are Januvia, Fiasp, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, and Embruvica. Access the Regulatory NewsBREAK to learn more.
Related
On May 22, 2025, the President’s Make America Healthy Again Commission published the MAHA report. The report raises concerns about the chronic childhood disease, processed food, environmental chemicals, lack of physical activity, mental health, and overmedicalization of American children.
On May 12, 2025, President Trump signed an Executive Order (EO) requiring agencies to take steps to encourage manufacturers to provide most-favored-nation pricing for prescription drugs.
On April 16, 2025, the Centers for Medicare and Medicaid Services (CMS) issued guidance on CY 2026 Part D Formulary Submissions (Guidance). The Guidance includes important dates related to CY 2026 formulary submissions.
Featured News & Resources
See Full Calendar
National Meetings
Midwest AMCP Chicago Day of Education
National Meetings
Mountain West Pharmacy Summit
Other Events
Northeast Day of Education
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
